1 / 24

Use of disease surveillance to inform new vaccine introduction

Use of disease surveillance to inform new vaccine introduction. Insert name of Presenter Annual Regional Conference on Immunization (ARCI). Dar-es-Salaam , Tanzania 10 to 12 December 2012. Introduction.

azra
Télécharger la présentation

Use of disease surveillance to inform new vaccine introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Use of disease surveillance to inform new vaccine introduction Insert name of Presenter Annual Regional Conference on Immunization (ARCI). Dar-es-Salaam, Tanzania 10 to 12 December 2012 Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  2. Introduction • Pneumonia and diarrhoea are the common causes of under 5s morbidity and mortality globally, causing 29% of deaths ≈ 2 mill. lives lost each year, • 90% occur in sub-Saharan Africa and South Asia. • In Tanzania they cause nearly one-third of all U5 deaths. • Rotavirus and Pneumococcal infants account for a significant proportions of these data. Source: World Health Report 2008 Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  3. Introduction: Prevalence • The reported prevalence of Pneumococcal infections in Tanzania is between- (data to be added) • Local Studies reported prevalence rotavirus infection of 8.4 -43% (Brookfield e al 1976, Mhalu et a 1992, Sam et al 1992,Temu M et al 2002, , Gascon et al – 2000, Moyo et al 2007, Temu A et al 2009) • PBM+IBD/Rotavirus surveillance was initiated in Tanzania in July 2001. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  4. New Vaccine Surveillance • Rotavirus/IBD/PBM surveillance was initiated Tanzania for the following purposes; • To estimate the incidence of hospitalizations associated with rotavirus/IBD among under-fives. • To determine the age and seasonal distribution of hospitalizations associated with rotavirus/IBD among under-fives. • To estimate the proportion of diarrhoea/ IBD hospitalizations attributable to rotavirus/HiB, pneumococcal among children under-fives. • To identify and characterize the prevalent strains in preparation for the introduction of vaccines. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  5. New Vaccine Surveillance sites Invasive bacterial Disease (IBD) inclPaediatric Bacterial Meningitis (PBM) surveillance. • Initiated at Muhimbili National Hospital in Oct 2001. • Muheza DDH in 2005. • Hydom hospital in 2007 • Bugandomedical centre in 2010. Rotavirus Gastroenteritis surveillance (RGS) • Initiated in Tanga (Bombo Hospital) – 2007. • Zanzibar (Mnazi Mmoja) and Mwanza (Bugando Medical Centre)- 2010. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  6. Methodology: Rotavirus Using WHO SOPs for rotavirus surveillance • Children under 5 years of age who were hospitalized with acute diarrhea were enrolled, and their stool specimens were collected. • Enzyme immunoassay- DAKO kits were used to detect rotavirus. • Rotavirus positive samples were sent to Regional reference laboratory (RRL) in Medunsa for quality control and genotyping. • Rotavirus strains were characterized for G and P types with use of a reverse-transcriptase polymerase chain reaction (RT-PCR). Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  7. Results: Rotavirus • From Nov 2007-June 2012; 2022 children were enrolled into the surveillance. • 1998 (98%) stool samples were collected and 796 (40%) were positive for rotavirus. • 308 (38.6%) specimens were sent to Regional Reference laboratory (RRL) for genotyping. • Infection was all year around with seasonal peaks and seasonal peaks, varied from year to year Jan-Feb in the first 2 years and Apr-June in the last two years. • 88% of all rotavirus infections occurred among children below one year of age. • Rotavirus infection was associated with a prolonged hospital stay and dehydration. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  8. Incidence of Rotavirus cases quarterly Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  9. Rotavirus Positive cases by age group From Nov 2007 to June 2012 Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  10. Rotavirus circulating genotypes 2008 - 2011 Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  11. Methodology: Hib-PBM Surveillance • Active sentinel surveillance of PBM was carried out in accordance with WHO/AFRO guideline with enhancement to include invasive disease by netSpear- at Muheza site. • LP was performed on all Suspected Bacteria Meningitis after obtaining consent A suspected case of pediatric bacterial meningitis • child 0-59 months of age with • sudden onset of fever (>38◦C axillary or >38.5◦C rectal) and • at least one of the following: neck stiffness, bulging fontanelle, altered consciousness, irritability, petechial of purpural rash, toxic appearance or other meningeal signs. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  12. Methodology: Hib-PBM Surveillance • Meningitis was confirmed by isolation of H. influenzae, S. pneumoniae or N. meningitidisfrom CSF (or positive latex test, if available) • For IBD - Blood was collected from cases of septicaemia and sent to laboratory for inoculation in culture media and incubation • All isolates were stored at -20⁰C, later were sent to RRL- Kilifi Kenya for serotyping. • All data are entered in Epi-Info and analyzed according to standard indicators per WHO guidelines • Quality control was done regularly from regional reference laboratory Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  13. Results: PBM Surveillance • Between Oct 2001 and Dec 2008 BEFORE the introduction of Hib vaccine, a total of 2600 cases of suspected meningitis cases were reported from 3 sentinel sites. • 2540 (93%) had a lumbar puncture performed and results logged in the database. • 467 (17 %) of specimen were purulent, 215(46%) CSF specimen were purulent but culture results were negative. • 252 (56%) were culture positive, 53 (21%)for Haemophilusinfluenzaeand 68(26%) For S. Pneumoniae, and 138 (53%) for other organisms. • A total of 11 serotypes were isolated, 90 % of these isolates are present in PCV13 • AFTER the introduction of Hib vaccine, a total of 142 cases of suspected meningitis cases were reported from one sentinel site (Muheza DDH) and lumbar puncture performed. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  14. Results: PBM surveillance Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  15. Confirmed meningitis cases Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  16. Streptococcus pneumoniaesero types • Serotype 13 and Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  17. Data analysis, sharing and use of surveillance data • Hospital administration? • Clinicians • MOHSW Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  18. New Vaccine introduction • Evidence provided has led to Tanzania deciding to introduce 2 new vaccines • Rotavirus and pneumoccocalvaccine into the routine immunization programmein Jan 2013. • Vaccines to be introduced are • Rotarix - human monovalent vaccine G1[P8] with a potential for cross protection. • Pneumococcal conjugate vaccine 13. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  19. Preparation of introduction • Tanzania’s First Lady in the 1st National Advocacy meeting Activities done and on going, • expansion of cold chain at the national and regional region. • guidelines for NVI has been prepared and printed ready for distribution. • Cascaded trainings from National to health facility level. • Advocacy and sensitization to immunization stakeholdersincluding the media. • Community mobilization Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  20. Conclusion • Rotavirus infection is responsible for 40% of severe gastroenteritis in surveillance sites in Tanzania • G1P8, G8P4, G2P4 are responsible for 68% of Rotavirus infections • S. Pneumoniae is responsible for about 26% of paediatric meningitis in surveillance sites Tanzania. • while ……were the majority in Meningitic patients • It is important to continue with surveillance after vaccine introduction and also to monitor adverse events, efficacy of vaccine and possible genotype variability. • Tanzania is now preparing to introduce Rotavirus and Pneumococcal vaccines in Jan 2013 Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  21. Way forward: New Vaccine Surveillance • 2 more sites to conduct start new vaccine surveillance; Dar and Mbeya • To monitor efficacy of vaccine, possible genotype variability and AEFI. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  22. acknowledgements . • New vaccines Surveillance Sentinel sites Teams- Mwanza, Hydom, Muheza, Tanga and Zanzibar • MOHSW/IVD - Tanzania Mainland and Zanzibar • WHO Country Office • WHO AFRO • RRL-Medunsa- University of Limpopo • Other partners, donors and stake holders in NVI Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  23. Thank you!!!! Ahsantenisana!!! Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

  24. Introduction: Pneumonia • Invasive pneumococcal disease is caused by the bacterium Streptococcus pneumoniae • Clinical manifestations of S. pneumoniae infections in young children are serious and include pneumonia, meningitis, sepsis, bacteremia, otitis media, abscesses, and bone and joint infections. • Worldwide, it is the most common cause of bacterial pneumonia mortality and the most severe cause of bacterial meningitis in children under five years of age. Annual Regional Conference on Immunization (ARCI); Dar-es-salaam, Tanzania, 10-12 December 2012

More Related